Project title: DEVICE FOR DIRECT MONITORING OF LUNG FUNCTIONALITY

Company name : INCA MEDICAL SYSTEMS LTD.

LTD.

TECHNOLOGICAL FIELD
Health Care, Medical Devices

KEY WORDS
Health Care, Medical
Devices

PROJECT SUMMARY
INCA is developing a groundbreaking device for direct monitoring
of lung functionality. The device is aimed at mechanically
ventilated patients in critical or chronic conditions as well as
ambulatory patients suffering from acute or chronic lung disease.

Functional Residual Capacity (FRC) of the human lung is known to
be a substantial physiological indicator of lung performance.
Currently, there is no practical procedure for fast, real-time
FRC measurement in mechanically ventilated patients. Physicians
set ventilation parameters using physical measurements as
pressure, flow and volume. These parameters do not represent the
lung area available for gas exchange. Over-inflation may cause
severe lung damage up to tissue disruption. Under-inflation may
cause atelectasis (lung collapse) hypoxemia and severe physical
consequences. "Real-time" FRC data will improve ventilation
quality, and prevent further lung damage.

The system includes a monitoring device and sensors in a
disposable tube connected to the patients' breathing circuit. The
volume of the FRC is automatically calculated by the monitoring
device, based on measurements of the breathing gases, using
calculus based formulas.

INCA's monitoring system will be assembled as an add-on device
fitting any common ventilation system. The company will seek OEM
agreements with major ventilator manufacturers during the
development process or subsequently.

ADVANTAGES
* Currently there is no practical method for real time FRC
monitoring
* Stand alone product- can work with any available ventilator
* Very accurate and shows minimal variance between repeated
measurements
* Measurement takes few seconds, does not interfere with patients
treatment
* Easy regulatory process
* Short time to market

TARGET MARKET
INCA's FRC measurement device targets primarily ventilated
patients. It is also targeted for lung functionality monitoring
in spontaneously breathing patients suffering from acute or
chronic lung diseases and healthy individuals (sports medicine).
The estimated total available market for ventilated patients is
$1B.
The market for independently Breathing Patients is Estimated at
few $B's.

ENTREPRENEURS
Dr. Yaron Bar-Lavie - MD, Founder, Director,
Department of Critical Care Medicine Rambam Medical Center,
Haifa, Israel
Mr. Zur Feldman - Chairman, Experience in
the high tech and VC industry in Israel and US.
Ms. Sivan Tali - CEO, Experience in
managing life science startup companies
Mr. Mark Shahar - Chief Technology Officer,
a serial entrepreneur, involved in the development of various
devices targeting the respiratory system

PROJECT STATUS
The company holds a working prototype, and showed proof of
concept in mechanically ventilated anesthetized pigs. Furthermore
the device was tested in a comparative study against a
commercially available device and showed a significant
superiority.
Provisional patent application has been submitted in April 2008.

COOPERATION REQUIRED
Not required yet.
---------------------------------------------
TEL: 972-4-6818801 972-54-6833173 FAX: 972-4-6818806 EMAIL:
sivant@technion.ac.il

Request for more information, about this project.

Note - you have to be registered in this server to request information. If you haven't done so yet, please:
Register in this server and your requests will be forwarded to the developer, who will contact you directly

List of projects that you already requested more information about